ES2196078T3 - Nuevo intermediario para la produccion de un derivado de piridina y procedimiento para producir este derivado. - Google Patents

Nuevo intermediario para la produccion de un derivado de piridina y procedimiento para producir este derivado.

Info

Publication number
ES2196078T3
ES2196078T3 ES95932208T ES95932208T ES2196078T3 ES 2196078 T3 ES2196078 T3 ES 2196078T3 ES 95932208 T ES95932208 T ES 95932208T ES 95932208 T ES95932208 T ES 95932208T ES 2196078 T3 ES2196078 T3 ES 2196078T3
Authority
ES
Spain
Prior art keywords
formula
represented
produce
procedure
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95932208T
Other languages
English (en)
Inventor
Syotaro Watanabe
William R Kem
Hun Ju Lee
Makoto Kajitani
Kazuo Maruhashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
University of Florida
Original Assignee
Taiho Pharmaceutical Co Ltd
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd, University of Florida filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2196078T3 publication Critical patent/ES2196078T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

ESTA INVENCION SE REFIERE A: (1) UN COMPUESTO REPRESENTADO POR LA FORMULA (V), SU TAUTOMERO Y UNA MEZCLA DE LOS MISMOS; (2) UN PROCEDIMIENTO PARA PRODUCIR EL COMPUESTO REPRESENTADO POR LA FORMULA ARRIBA MENCIONADA (V), SU TAUTOMERO O UNA MEZCLA DE LOS MISMOS, QUE COMPRENDE LA REACCION DE N-VINILPIPERIDONA REPRESENTADA POR LA FORMULA (I) CON UN NICOTINATO REPRESENTADO POR LA FORMULA (II), EN DONDE R REPRESENTA UN GRUPO DE ALQUILO BAJO, EN PRESENCIA DE UN ALCOXIDO DE SODIO; (3) UN PROCEDIMIENTO PARA PRODUCIR UN DERIVADO DE PIRIDINA REPRESENTADO POR LA FORMULA (III), QUE COMPRENDE LA PRODUCCION DEL COMPUESTO REPRESENTADO POR LA FORMULA (V), SU TAUTOMERO O UNA MEZCLA DE LOS MISMOS MEDIANTE EL PROCEDIMIENTO DESCRITO EN EL PUNTO ANTERIOR (2), Y A CONTINUACION TRATAR EL COMPUESTO OBTENIDO CON UN ACIDO; Y (4) UN PROCEDIMIENTO PARA PRODUCIR UN DERIVADO DE PIRIDINA REPRESENTADO POR LA FORMULA (IV), EN EL CUAL EL TRATAMIENTO CON UN ACIDO COMO SE DESCRIBE EN EL PUNTO ANTERIOR (3) ES SEGUIDO DE OTRO TRATAMIENTO CON UNA BASE. ASI, LA PRESENTE INVENCION PROPORCIONA PROCEDIMIENTOS INDUSTRIALES PARA PRODUCIR DERIVADOS DE PIRIDINA REPRESENTADOS POR LAS FORMULA (III) Y (IV) DE FORMA SEGURA, ECONOMICA, FACIL Y EFICAZ SIN UTILIZAR NINGUN REACTIVO PELIGROSO.
ES95932208T 1994-09-22 1995-09-21 Nuevo intermediario para la produccion de un derivado de piridina y procedimiento para producir este derivado. Expired - Lifetime ES2196078T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP25272694A JP3219946B2 (ja) 1994-09-22 1994-09-22 新規製造中間体及びピリジン誘導体の製造方法

Publications (1)

Publication Number Publication Date
ES2196078T3 true ES2196078T3 (es) 2003-12-16

Family

ID=17241414

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95932208T Expired - Lifetime ES2196078T3 (es) 1994-09-22 1995-09-21 Nuevo intermediario para la produccion de un derivado de piridina y procedimiento para producir este derivado.

Country Status (7)

Country Link
US (1) US5734059A (es)
EP (1) EP0787724B1 (es)
JP (1) JP3219946B2 (es)
CA (1) CA2200604C (es)
DE (1) DE69530408T2 (es)
ES (1) ES2196078T3 (es)
WO (1) WO1996009300A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2495248A1 (en) * 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
US20050288333A1 (en) * 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
WO2018064529A1 (en) 2016-09-29 2018-04-05 The Uab Research Foundation Methods and compositions for increasing mucus clearance
PT3728215T (pt) * 2017-12-22 2021-11-22 Siegfried Ag Proceso numa única etapa para a preparação de nicotina racémica através de reação de nicotinato de etilo com n-vinilpirrolidona na presença de etanolato de sóio ou etanolato de potássio ou misturas dos mesmos
WO2020099490A1 (en) 2018-11-14 2020-05-22 Novozymes A/S Oral care composition comprising enzymes
CN116322625A (zh) 2020-08-24 2023-06-23 诺维信公司 包含果聚糖酶的口腔护理组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105071C (en) * 1991-03-01 2002-05-14 John A. Zoltewicz Use of nicotinic analogs for treatment of degenerative diseases of the nervous system

Also Published As

Publication number Publication date
CA2200604A1 (en) 1996-03-28
EP0787724B1 (en) 2003-04-16
JP3219946B2 (ja) 2001-10-15
EP0787724A4 (en) 1998-01-07
WO1996009300A1 (fr) 1996-03-28
DE69530408T2 (de) 2003-10-30
JPH0892242A (ja) 1996-04-09
US5734059A (en) 1998-03-31
DE69530408D1 (de) 2003-05-22
EP0787724A1 (en) 1997-08-06
CA2200604C (en) 2001-04-10

Similar Documents

Publication Publication Date Title
ES2058396T3 (es) N-isopropilanilidas de acido heteroariloxiacetico.
DK1029861T3 (da) Benzisothiazol-piperazinylderivat og dets anvendelse som neuroleptikum
ES2130232T3 (es) N,n'-diacilhidrazinas n' sustituidas como insecticidas.
PT953283E (pt) Metodo para producao no local de um sistema desinfectante de acido peracetico
ES2085129T3 (es) Nuevos derivados de la eritromicina, su procedimiento de preparacion y su aplicacion como medicamentos.
ES2178779T3 (es) Nuevas amidas de acidos de piridil alcanos como agentes citoestaticos e inmunosupresores.
PT80981B (pt) Processo para a realizacao de reacoes de cloracao substitutiva de compostos organicos por meio de cloro molecular na presenca de um produto clorado que serve de iniciador radicalar
ES2058089T3 (es) Un procedimiento para la preparacion de un nuevo derivado de prolinal.
ES2196078T3 (es) Nuevo intermediario para la produccion de un derivado de piridina y procedimiento para producir este derivado.
ES2045009T3 (es) El acido taurohyodesoxicolico para la terapia de calculosis del tracto biliar y de la dispepsia biliar.
ES2032955T3 (es) Sal sodica anhidra cristalina de 5-cloro-3-(2-tenoil)-2-oxindol-1-carboxamida.
ES2096973T3 (es) Fosfazenos que contienen radicales organicos de silicio, proceso para su preparacion, y su empleo.
DK0575189T3 (da) Organiske cerium/(IV)-forbindelser og deres fremstilling og anvendelse
ES2071666T3 (es) Derivados de pirazoloisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ATE323602T1 (de) Bildaufzeichnungsmaterial und flachdruckplatte mit diesem bildaufzeichnungsmaterial
EG16053A (en) New thieno pyridinone derivatives,process for its preparation and therapeutic applications thereof
ES2114115T3 (es) Procedimiento y nuevos productos intermedios para la obtencion de triazolinonas.
AR005072A1 (es) Derivados del acido 2-(o-(pirimidin-4-il) metilenoxi) fenilacetico, composiciones formuladas con dichos derivados, utilizacion de dichos derivadosy de dichas composiciones para combatir hongos daninos y las alimanas y procedimiento para preparar dichas composiciones y procedimiento de aplicacion
TW362982B (en) Fire fighting compositions
ES2060235T3 (es) Un proceso para la produccion de una bencilamina.
ES2072492T3 (es) Derivados de acido piridinalqueno- y -aminooxialcano-carboxilico sustituidos por fenilsulfonamida.
ES2158476T3 (es) Procedimiento para la preparacion de compuestos distirildifenilicos.
ES2035102T3 (es) Compuestos que contienen hierro biodisponible, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2061618T3 (es) Procedimiento para la fabricacion de derivados de acido fosforico y productos intermedios.
KR910009657A (ko) 캡토프릴의 직접 단리 방법